Please login to the form below
telaprevir
This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.
2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
Latest news
-
Access to new hep C treatments put under the spotlight
telaprevir). But NICE has not recommended the use of Daklinza-based regimens to treat patients with genotype 3 of the disease - which accounts for around 45% of all cases in England,
-
FDA approves four new medicines across multiple areas
and Vertex' Incivek (telaprevir).
-
J&J starts to feel biosimilar competition bite
toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
-
Top biotech firms saw sales jump in 2014
Dion added: “This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
-
The end of hepatitis C?
The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some ... Merck &Co. III. paritaprevir.
More from news
Approximately 0 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2013
172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
-
Interview: Cesar Rodriguez, Janssen
Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Digital Account Director
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
-
Senior Medical Writer
-
Salary TBC
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Health Consultant - Brand Comms
-
Competitive Salary
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
- Brain power: fresh approaches to Alzheimer’s drug discovery
- Roche, AbbVie hit by clinical hold for Venclexta in myeloma
- BMS defends Celgene buyout ahead of shareholder vote
- Apple Watch shows promise in heart study, but doctors sceptical
- Is May’s Brexit deal sinking after Speaker's procedural torpedo?
- Roche gets FDA nod for Tecentriq in small cell lung cancer
PMHub
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...
Latest intelligence
- Brain power: fresh approaches to Alzheimer’s drug discovery
- New alliances are learning from past mistakes and breaking down research barriers...
- Genomics integration: can the NHS rise to the challenge?
- Experts gather to discuss the UK’s genomic landscape...
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
Quick links
Infographics
